-transparent.png){kind=logo}
We studied the effects of vitamin D metabolites in 29 patients established on chronic hemodialysis. The patients were divided into four groups; one was treated with 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] 0.5 microgram/day, one with 24R,25-dihydroxyvitamin D3 [24,25-(OH)2D3] 10 micrograms/day, and one with both metabolites. The control group was not given vitamin D. Plasma levels of both metabolites were low before treatment. 1,25-(OH)2D3 levels became normal, and 24,25-(OH)2D3 increased to supranormal levels after administration of the corresponding metabolite. Combined treatment produced still higher plasma levels of 24,25-(OH)2D3, suggesting an interaction between the two metabolites. Patients receiving 1,25-(OH)2D3 alone had a greater increase in plasma calcium than those receiving both metabolites. In control patients, hyperparathyroid bone disease worsened over the 10-month observation period. 1,25-(OH)2D3 improved hyperparathyroid bone disease in most patients, as reflected by a reduction in osteoclast and osteoblast numbers, but had no demonstrable effect on mild osteomalacia. 24,25-(OH)2D3 had no significant effect on plasma biochemistry or bone histology, and the effect of combined treatment on histology was similar to that of 1,25-(OH)2D3 alone. Stainable bone aluminum increased slightly in patients given 1,25-(OH)2D3, but aluminum did not affect the response to treatment. We conclude that 1,25-(OH)2D3 is a useful agent in the treatment of renal bone disease, but no therapeutic role is apparent for 24,25-(OH)2D3.
C R Dunstan, and
E Hills, and
A W Norman, and
J E Bishop, and
E Mayer, and
S Y Wong, and
Y Eade, and
J R Johnson, and
C R George, and
P Collett
November 1985,
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
C R Dunstan, and
E Hills, and
A W Norman, and
J E Bishop, and
E Mayer, and
S Y Wong, and
Y Eade, and
J R Johnson, and
C R George, and
P Collett
December 1979,
Research communications in chemical pathology and pharmacology,
C R Dunstan, and
E Hills, and
A W Norman, and
J E Bishop, and
E Mayer, and
S Y Wong, and
Y Eade, and
J R Johnson, and
C R George, and
P Collett
January 1980,
Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association,
C R Dunstan, and
E Hills, and
A W Norman, and
J E Bishop, and
E Mayer, and
S Y Wong, and
Y Eade, and
J R Johnson, and
C R George, and
P Collett
January 1987,
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
C R Dunstan, and
E Hills, and
A W Norman, and
J E Bishop, and
E Mayer, and
S Y Wong, and
Y Eade, and
J R Johnson, and
C R George, and
P Collett
February 2007,
Steroids,
C R Dunstan, and
E Hills, and
A W Norman, and
J E Bishop, and
E Mayer, and
S Y Wong, and
Y Eade, and
J R Johnson, and
C R George, and
P Collett
October 1987,
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
C R Dunstan, and
E Hills, and
A W Norman, and
J E Bishop, and
E Mayer, and
S Y Wong, and
Y Eade, and
J R Johnson, and
C R George, and
P Collett
January 1989,
Endocrinology,
C R Dunstan, and
E Hills, and
A W Norman, and
J E Bishop, and
E Mayer, and
S Y Wong, and
Y Eade, and
J R Johnson, and
C R George, and
P Collett
January 1984,
Metabolic bone disease & related research,
C R Dunstan, and
E Hills, and
A W Norman, and
J E Bishop, and
E Mayer, and
S Y Wong, and
Y Eade, and
J R Johnson, and
C R George, and
P Collett
October 1990,
Calcified tissue international,
C R Dunstan, and
E Hills, and
A W Norman, and
J E Bishop, and
E Mayer, and
S Y Wong, and
Y Eade, and
J R Johnson, and
C R George, and
P Collett
September 1980,
General and comparative endocrinology,
